Clinical Trial Update: Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating regorafenib in combination with cetuximab or panitumumab for unresectable, locally advanced, or metastatic colorectal cancer. Results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• Stivarga (regorafenib)
• Vectibix (panitumumab)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: BRAF V600E Negative, KRAS Gene Mutation Negative | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-09-27